Onsdag 13 November | 08:01:10 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2024-11-13 08:00 Kvartalsrapport 2024-Q3
2024-08-07 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning PHO 0.00 NOK
2024-05-23 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-09 - Kvartalsrapport 2023-Q2
2023-05-10 - Kvartalsrapport 2023-Q1
2023-05-04 - X-dag ordinarie utdelning PHO 0.00 NOK
2023-05-03 - Årsstämma
2023-02-24 - Bokslutskommuniké 2022
2023-02-23 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-08-10 - Kvartalsrapport 2022-Q2
2022-05-11 - Kvartalsrapport 2022-Q1
2022-04-29 - X-dag ordinarie utdelning PHO 0.00 NOK
2022-04-28 - Årsstämma
2022-02-23 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-11 - Kvartalsrapport 2021-Q2
2021-07-28 - Extra Bolagsstämma 2021
2021-05-21 - X-dag ordinarie utdelning PHO 0.00 NOK
2021-05-20 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-03-03 - Bokslutskommuniké 2020
2020-11-10 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-06-11 - X-dag ordinarie utdelning PHO 0.00 NOK
2020-06-10 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-07 - Kvartalsrapport 2019-Q2
2019-06-19 - Extra Bolagsstämma 2019
2019-05-14 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning PHO 0.00 NOK
2019-05-09 - Årsstämma
2019-02-27 - Bokslutskommuniké 2018
2018-11-08 - Kvartalsrapport 2018-Q3
2018-08-08 - Kvartalsrapport 2018-Q2
2018-05-23 - Kvartalsrapport 2018-Q1
2018-05-11 - X-dag ordinarie utdelning PHO 0.00 NOK
2018-05-09 - Årsstämma
2018-02-27 - Bokslutskommuniké 2017
2017-11-08 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-23 - Kvartalsrapport 2017-Q1
2017-04-28 - X-dag ordinarie utdelning PHO 0.00 NOK
2017-04-27 - Årsstämma
2017-02-15 - Bokslutskommuniké 2016
2016-11-15 - Kvartalsrapport 2016-Q3
2016-08-23 - Kvartalsrapport 2016-Q2
2016-05-10 - Kvartalsrapport 2016-Q1
2016-04-29 - X-dag ordinarie utdelning PHO 0.00 NOK
2016-04-28 - Årsstämma
2016-02-11 - Bokslutskommuniké 2015
2015-10-29 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-05-06 - Kvartalsrapport 2015-Q1
2015-05-02 - X-dag ordinarie utdelning PHO 0.00 NOK
2015-04-30 - Årsstämma
2015-02-12 - Bokslutskommuniké 2014
2014-11-06 - Kvartalsrapport 2014-Q3
2014-08-26 - Kvartalsrapport 2014-Q2
2014-05-28 - X-dag ordinarie utdelning PHO 0.00 NOK
2014-05-27 - Årsstämma
2014-05-07 - Kvartalsrapport 2014-Q1
2014-02-27 - Bokslutskommuniké 2013
2013-10-23 - Kvartalsrapport 2013-Q3
2013-08-22 - Kvartalsrapport 2013-Q2
2013-05-23 - X-dag ordinarie utdelning
2013-05-22 - Årsstämma
2013-04-25 - Kvartalsrapport 2013-Q1
2013-02-28 - Bokslutskommuniké 2012
2012-10-26 - Kvartalsrapport 2012-Q3
2012-08-24 - Kvartalsrapport 2012-Q2
2012-05-10 - Årsstämma
2012-04-26 - Kvartalsrapport 2012-Q1
2012-02-16 - Bokslutskommuniké 2011
2011-10-26 - Kvartalsrapport 2011-Q3
2011-08-18 - Kvartalsrapport 2011-Q2
2011-04-27 - Kvartalsrapport 2011-Q1
2011-04-27 - Årsstämma
2011-02-17 - Bokslutskommuniké 2010
2010-10-27 - Kvartalsrapport 2010-Q3
2010-08-19 - Kvartalsrapport 2010-Q2
2010-04-28 - Kvartalsrapport 2010-Q1
2010-02-19 - Bokslutskommuniké 2009
2009-11-26 - X-dag bonusutdelning

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Photocure är verksamma inom medicinteknik. Bolaget specialiserar sig inom lösningar för fotodynamisk teknik. Idag används lösningarna för behandling av sjukdomar som föranlett cancer i urinblåsan och HPV. Huvudmarknaderna återfinns inom dermatologi och onkologi, där produkterna används av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1993 och har huvudkontor i Oslo, Norge.
2024-09-30 08:00:00

Press Release - Oslo, Norway, September 30, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international multicenter Phase III clinical study data for its non-surgical treatment candidate Cevira[®] (APL-1702) for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) has been published by the 27[th] Chinese Society of Clinical Oncology (CSCO) Annual Meeting as a poster, focusing on the analysis of different age subgroups regarding the six-month pathological regression rate and HPV clearance rate.

This Phase III clinical trial is a prospective, randomized, double blind, placebo controlled, multi-center clinical study, which has reached its primary efficacy endpoint and exhibited good safety.

Furthermore, the study results included the pathological regression rate (defined as the proportion of subjects with a pathological regression to CIN1 or normal tissue) at the 6[th] month across different age subgroups. Both the "≥20 and <30 years" subgroup and the "≥30 and <40 years" subgroup showed an increase of 15% to 20% in the pathological regression rate in the APL-1702 group compared to the placebo control group. No cervical cancer events were reported, suggesting a significant therapeutic potential of APL-1702 in the HSIL population aged 20 to 40 years.

Regarding HPV clearance rate, in the "≥20 and <30 years" age group, the APL-1702 group showed enhancements in the overall HPV clearance rate, HPV16-positive clearance rate, and HPV16/18-positive clearance rate compared to the placebo control group. The patients' number in the "<20 years" and "≥40 years" age groups were limited, thus the results in these age groups require a validation study with a larger sample size. Overall, APL-1702 not only facilitates the regression from HSIL to LSIL but also demonstrates the ability to induce clearance of high-risk HPV infections.

Read Asieris' full media release here: https://asieris.com/asieris-unveils-results-for-the-first-time-at-2024-csco-conference-the-subgroup-analysis-of-pathological-regression-rate-and-hpv-clearance-rate-at-6-months-in-different-age-groups-of-the-non-surgical/

Note to editors:

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.
This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

About Cevira[®]
Cevira[®] (APL-1702) is a photodynamic drug-device combination product in development. Based on the principles of photodynamic therapy, the Cevira product aims to use a photosensitizer in combination with light activation to produce a therapeutic effect as a non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL) in patients aged 18 years and above, excluding carcinoma in situ.
Photocure developed Cevira through Phase I and Phase II trials, and the global rights for development and commercialization were out-licensed to Asieris Meditech Co., Ltd in 2019. In November 2020 Asieris initiated the phase III clinical trial for APL-1702 (Cevira) which achieved its primary endpoint in September 2023, Clinical trial number: NCT04484415 (https://classic.clinicaltrials.gov/ct2/show/NCT04484415). The new drug application for APL-1702 was accepted by the National Medical Products Administration (NMPA) in May 2024.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com

About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.